COMMUNIQUÉS West-GlobeNewswire

Devenez membre PREMIUM

Accèdez sans limite aux 15 000 actualités du site
et recevez gratuitement chaque semaine,
la Newsletter Santé log avec les actus Santé à ne pas manquer !

S'abonner
29€ TTC/an

Je suis déjà membre PREMIUM

Se connecter

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
10/04/2025 - 13:35
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE [...]
Glass House Brands and Eaze Partner to Launch PLUS Cannabis Gummies in Florida
10/04/2025 - 13:55
LONG BEACH, Calif. and TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Ace Vision Group to Host “Take the Presbyopia Challenge” Event and Present Scientific Posters at 2025 ASCRS Annual Meeting
10/04/2025 - 14:00
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ace Vision Group, Inc . (“AVG” or “the Company”), an emerging medical device company on the forefront of pioneering a laser microporation therapy for the aging eye, today [...]
Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025
10/04/2025 - 14:00
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April 10, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
10/04/2025 - 14:00
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both [...]
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
10/04/2025 - 14:00
A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in Indonesia and [...]
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor
10/04/2025 - 14:00
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
10/04/2025 - 14:00
Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the [...]
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors
10/04/2025 - 14:00
Dansey, a former senior executive at Pfizer and Seagen, Inc., brings extensive experience in immuno-oncology and drug development Board appointment reinforces Company’s commitment to advancing Jankistomig, a one-of-a- [...]
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
10/04/2025 - 14:00
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE [...]
Avalyn to Participate in Upcoming Investor Conference in April
10/04/2025 - 14:00
CAMBRIDGE, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening pulmonary diseases, [...]
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
10/04/2025 - 14:00
DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 or DIAMOND-2 Phase 3 trials at an industry-leading [...]
Evaxion to present at World Vaccine Congress
10/04/2025 - 14:00
Congress will take place April 21-24, 2025, in Washington, D.C. COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI- [...]
VitalHub Announces Recommended Cash Acquisition of Induction Healthcare Group PLC
10/04/2025 - 14:00
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX: VHIBF) is pleased to announce that it has agreed the terms and conditions of a recommended cash acquisition to [...]
La Commission européenne approuve la quadrithérapie à base de DARZALEX® (daratumumab) par voie sous-cutanée de Johnson & Johnson chez les patients atteints d’un myélome multiple nouvellement diagnostiqué, quelle que soit leur éligibilité à la greffe
10/04/2025 - 14:11
Cet approbation renforce l’utilisation du daratumumab en traitement fondamental chez les patients atteints d’un myélome multiple nouvellement diagnostiqué, en faisant ainsi le seul anticorps anti-CD38 pour tous les [...]
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
10/04/2025 - 14:25
Vancouver, Canada, April 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
10/04/2025 - 14:30
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT ) (" Conduit " or the “ Company ”) today announced that its Board of Directors has authorized a [...]
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel
10/04/2025 - 14:30
Latest granted patents reinforce Pluri’s position as a leader in Mucosal- A ssociated I nvariant T ( “ MAIT ” ) cell -based cell therap ies for solid cancers Pluri’s MAIT platform enable s commercial scale production of [...]
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
10/04/2025 - 14:30
- Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious cardiovascular and musculoskeletal complications - - Findings highlight the urgent need [...]

Pages